Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to 0.86.

  • Gyre Therapeutics' Equity Ratio rose 965.06% to 0.86 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.86, marking a year-over-year increase of 965.06%. This contributed to the annual value of 0.78 for FY2024, which is 67773.79% up from last year.
  • Per Gyre Therapeutics' latest filing, its Equity Ratio stood at 0.86 for Q3 2025, which was up 965.06% from 0.85 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Equity Ratio registered a high of 0.95 during Q2 2022, and its lowest value of 2.28 during Q2 2023.
  • For the 5-year period, Gyre Therapeutics' Equity Ratio averaged around 0.46, with its median value being 0.78 (2024).
  • Per our database at Business Quant, Gyre Therapeutics' Equity Ratio crashed by 34090.59% in 2023 and then skyrocketed by 67773.79% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Equity Ratio (Quarter) stood at 0.74 in 2021, then increased by 15.43% to 0.85 in 2022, then plummeted by 115.94% to 0.14 in 2023, then soared by 677.74% to 0.78 in 2024, then grew by 9.88% to 0.86 in 2025.
  • Its last three reported values are 0.86 in Q3 2025, 0.85 for Q2 2025, and 0.8 during Q1 2025.